No-shows are a scheduling problem, not a patient problem.

Healthcare no-show rates respond more to scheduling design than to patient behavior. Predictive models targeting at-risk appointments are reducing no-shows by up to 70 percent in well-designed deployments.

There is a framing problem in how healthcare organizations talk about no-shows. The default conversation treats no-shows as a patient-behavior issue, addressed through reminder systems and policies. The data suggests something different. Patients miss appointments at predictable rates determined by the appointment's characteristics: time of day, lead time from booking, day of week, patient history, weather, transit availability, and a dozen other factors. The patients are not the variable. The scheduling design is the variable.

12 to 30%
typical outpatient no-show rate band, with predictable concentration in specific slot characteristics
92%
no-show prediction accuracy achieved in 2024 peer-reviewed tertiary hospital study
+10%
monthly attendance lift after AI scheduling intervention in same study

The numbers that actually matter

Reported no-show rates in published literature vary from 12 percent to 80 percent depending on setting, with most outpatient operations falling in the 15 to 30 percent band [1]. The cost is real. The US healthcare system loses over USD 150 billion annually to no-shows, with individual physicians losing an average of USD 200 per unused time slot [2]. But headline cost numbers are less useful than the structural insight: the variance within a single clinic between best and worst scheduling configurations is often larger than the variance between clinics. Which is to say, scheduling design dominates patient population characteristics.

The patients are not the variable. The scheduling design is the variable.

Why predictive AI works here

Predictive models in healthcare scheduling reached production maturity around 2023. A 2024 peer-reviewed study published in MDPI Healthcare on an AI-based appointment system at a tertiary hospital found that the model could predict 92 percent of no-show patients accurately, and the system increased monthly attendance by 10 percent while raising hospital capacity utilization by 6 percent [3]. The mechanism is not magical. The model takes historical attendance data, identifies the factors that correlate with no-show in this specific clinic with this specific patient mix, and produces a risk score per appointment. The model is then used not to predict for prediction's sake but to drive intervention: extra reminders, schedule double-booking on high-risk slots, waitlist activation, or rescheduling to lower-risk windows.

Healthcare administrative staff using scheduling software
The intervention layer is where the model meets the workflow. Without it, prediction is theatre.

The intervention layer is where it works or fails

A 70 percent reduction in no-show rate, cited in cases where predictive models drive scheduling intervention [4], is not the model's achievement. It is the achievement of the workflow built around the model. A high-risk score with no intervention produces the same no-show rate as no model. The interventions that have evidence behind them include: tiered reminder cadence (more frequent and more channels for higher-risk appointments), proactive rescheduling offers when the model identifies a low-fit slot, waitlist activation that fills predicted no-show slots in the day before, and patient-side scheduling autonomy for high-risk patients so they can choose their own time within a window. Each intervention is well-understood. The combination, tuned to the model's output, is what produces the cited reductions.

Hospitals are already adopting at scale

According to a 2024 study by the US Office of the National Coordinator for Health IT, 71 percent of hospitals reported using predictive AI integrated into their electronic health records, with scheduling facilitation being one of the fastest-growing use cases, up 16 percentage points from 2023 [5]. The pattern is similar in European hospital systems, with the EU AI Act's healthcare provisions providing the governance framework rather than the blocker. The trajectory is unambiguous: predictive scheduling is becoming standard practice in mature hospital operations, and the lag between adoption and impact is shrinking.

Three-quarters of US hospitals using predictive AI now have multiple entities accountable for evaluating the models. This is not optional governance.

The ethical layer that has to be addressed

Predictive models in healthcare scheduling raise specific ethical questions that pure logistics models do not. The model's features may correlate with demographic factors in ways that produce disparate impact. A clinic that uses no-show prediction to deprioritize at-risk patients risks worsening healthcare access for the populations most likely to miss appointments. The mitigation is design-level: the model's output drives intervention to support attendance, not to deprioritize patients. Three-quarters of hospitals using predictive AI now have multiple entities accountable for evaluating the models, with most conducting accuracy and bias evaluation as well as post-implementation monitoring [5]. This is not optional governance; it is the difference between a tool that improves access and a tool that degrades it.

What this means for Belgian healthcare

Two factors specific to the Belgian context. First, Belgian healthcare combines public and private provision with strong patient autonomy, which means scheduling interventions need to respect patient choice rather than impose them. The reminder-cadence and proactive-rescheduling layers fit this framing well; double-booking does not. Second, the EU AI Act, with healthcare-related high-risk system rules entering full application from August 2026, requires governance documentation that mid-market clinics are not always prepared for. Building the governance in from the start, including bias monitoring and human-in-the-loop decision authority, is more efficient than retrofitting it later [6].

The sequence for a clinic getting started

Three phases. Phase one: measure. Six months of historical no-show data, decomposed by appointment characteristics. Most clinics discover that 60 to 80 percent of no-shows concentrate in 20 to 30 percent of appointment slots, and the predictive features driving that concentration are usually three to five factors, not twenty. Phase two: pilot intervention without a model. Use the historical analysis to identify the highest-risk slots and apply the intervention layer manually for one quarter. The baseline improvement from this alone is often 20 to 30 percent of the eventual gain. Phase three: introduce the predictive model to optimize the interventions and extend them to lower-tier risk slots. The model's contribution at this stage is real but smaller than the analysis-driven baseline improvement.

What gets measured beyond no-show rate

No-show rate is the headline number but not the only one that matters. Three additional measures: capacity utilization (the proportion of scheduled clinic time actually delivering care), patient-perceived access (how long from booking request to consultation), and equity-of-access (whether the gains are distributed across patient populations or concentrated in already-attending segments). The published evidence shows that capacity utilization improvements of 5 to 8 percent are typical [3], and access measures improve in parallel. Equity-of-access is the measure most often missing from reported deployments, and the one most worth instrumenting from day one.

How Solazur works

From pattern to operating outcome.

Every Solazur engagement follows the same four-step model. The first step is short and free. The rest is measured against the operational metric you care about, not against vendor milestones.

  1. 01

    Free Operational Assessment

    A 90-minute readiness session. We map your operation against current automation patterns and identify two or three concrete opportunities.

    About the Operational Assessment
  2. 02

    Diagnostic and roadmap

    We assess workflow, data, and governance readiness, then propose a phased plan with measurable outcomes. No technology selected before the diagnosis is signed off.

    Automation Roadmap
  3. 03

    Partner-led delivery

    We orchestrate delivery, with Valenta as our principal AI and automation partner. You get a single point of accountability and global delivery capability.

    Managed AI Operation
  4. 04

    Operate and measure

    Solutions go live as a service, measured weekly against the success criteria defined in step 1. Iteration is continuous, not project-based.

    Operations Foundation

Sources

  1. PMC / NCBI Bookshelf. Predicting patient no-shows using machine learning: A comprehensive review. 2025. https://www.sciencedirect.com/science/article/pii/S2666521225000328
  2. NCBI / PMC. Bringing Precision to Pediatric Care: Explainable AI in Predicting No-Show Trends. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11939553/
  3. MDPI Healthcare (peer-reviewed). A Solution to Reduce the Impact of Patient No-Show Behavior on Hospital Operating Costs. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11545362/
  4. Healthcare AI industry analysis (peer-cited). Predictive models reducing appointment cancellations. 2024.
  5. US Office of the National Coordinator for Health IT (ASTP). Hospital Trends in the Use, Evaluation, and Governance of Predictive AI, 2023-2024. 2024. https://www.ncbi.nlm.nih.gov/books/NBK618497/
  6. European Commission. AI Act (Regulation EU 2024/1689). 2024. https://digital-strategy.ec.europa.eu/en/policies/regulatory-framework-ai
Related

More from Solazur Insights

No-shows cost more than missed revenue. They cost trust.

The CMR is the bottleneck. Fix it first.

Lifting OEE without lifting headcount.

Ready to have the conversation?

Book a free 90-minute Operational Assessment. We will identify two or three concrete automation opportunities in your operation.